Should I buy Doximity (DOCS) stock or is it too late?

Doximity · Health Care · price $26

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: B of A Securities — 74% of its targets hit on this sector (105 calls tested). It aims for $20 (-22 %), call made on June 30, 2026, maturing on June 30, 2027 (59 d ago).

The 3 reliable analysts $20-22 %

The 16 other firms $28.50+11 %

How to read it: the 3 reliable firms are not filtered by optimism — 0 aim above the price, 3 below, hence their $20 median. “The 16 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Doximity

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Canaccord Genuity	29 %	+8.4 %	7	$30 +17%
Baird	40 %	-18.7 %	5	$18 -30%
Needham	18 %	-25.0 %	11	$27 +6%
Raymond James	20 %	-36.6 %	10	$65 +154%
Morgan Stanley	29 %	-56.1 %	7	$35 +37%

In short — Should you invest in Doximity? Is it too late, still worth it? Analysts are split (35% buy, median target $27, i.e. +4%), and the most reliable on DOCS targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

The most reliable firm on DOCS, Barclays (50% hit rate, 2 scored calls), targets $27 (call made on August 21, 2026, maturing on August 21, 2027) (+6%) in its most recent call, and $63 (call made on December 9, 2025, maturing on December 9, 2026) (+146%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 20 ratings, 11 are neutral and 2 are sells.
Limited upside: the median target is only +4% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on DOCS

Median target $27 (+4%) · 20 ratings · Hold consensus

Strong Buy00%

Buy735%

Hold1155%

Sell210%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Doximity now?

We won't decide for you. The facts: 35% of analysts rate it a buy, median target $27 (+4%), and Barclays (most reliable on DOCS, 50%) targets $27. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Doximity?

Not according to analysts: the median target ($27) is still +4% above the current price ($26) (most reliable on DOCS: Barclays, 50%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Doximity still worth investing in?

It depends on the gap between the price ($26) and its estimated value: analysts target $27 on median (+4%), with 35% buys (most reliable on DOCS: Barclays, 50%). Cross-check with their real reliability on DOCS and the cautions above. Information, not advice.

What's the main risk in buying DOCS?

The consensus is not unanimous: of 20 ratings, 11 are neutral and 2 are sells.

→ Go deeper: the full Doximity profile (consensus, analyst reliability, price target, performance).